Cargando…

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar

Acute myocardial infarction (AMI) is generally attributed to coronary atherothrombotic disease. Platelet activation is essential for thrombus formation and is thus an important target for pharmacological intervention to prevent and treat AMI. Despite contemporary treatment with dual antiplatelet the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farag, Mohamed, Patel, Hiten, Gorog, Diana A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516206/ https://www.ncbi.nlm.nih.gov/pubmed/26229441 http://dx.doi.org/10.2147/DDDT.S68391

Ejemplares similares

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Thrombolysis and adjunctive therapy for acute myocardial infarction /
Publicado: (1993)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Determinants of Endogenous Fibrinolysis in Whole Blood Under High Shear in Patients With Myocardial Infarction
por: Kanji, Rahim, et al.
Publicado: (2022)

Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis
por: Niespialowska-Steuden, Maria, et al.
Publicado: (2017)

Non-ST-Segment Elevation Myocardial Infarction As Initial Thrombotic Event of Thrombotic Thrombocytopenic Purpura: A Rare Challenging Case
por: Mohamed, Khalid H, et al.
Publicado: (2023)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy—Current Data and Future Directions
por: Spinthakis, Nikolaos, et al.
Publicado: (2018)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

A rare cause of myocardial infarction with non-obstructive coronary arteries—case report of ST-segment elevation myocardial infarction caused by a mediastinal mass
por: Gue, Ying X, et al.
Publicado: (2018)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Myocardial infarction as a thrombotic complication of myeloproliferative disorders
por: Petrou, Emmanouil, et al.
Publicado: (2016)

Identification of a plasma metabolomic signature of thrombotic myocardial infarction that is distinct from non-thrombotic myocardial infarction and stable coronary artery disease
por: DeFilippis, Andrew P., et al.
Publicado: (2017)

The Challenge of High Coronary Thrombotic Events in Patients with ST-Segment Elevation Myocardial Infarction and COVID-19
por: Anghel, Larisa, et al.
Publicado: (2022)

Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy
por: Parodi, Guido, et al.
Publicado: (2010)

A case of repetitive myocardial infarction with unobstructed coronaries due to Churg–Strauss syndrome
por: Gue, Ying X, et al.
Publicado: (2019)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Incidence of thrombotic complications in COVID-19: On behalf of ICODE: The International COVID-19 Thrombosis Biomarkers Colloquium
por: Jenner, William J., et al.
Publicado: (2021)

Presence of bacterial DNA in thrombotic material of patients with myocardial infarction
por: Piñon-Esteban, P., et al.
Publicado: (2020)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Thrombotic Events Associated to Aspirin Therapy
por: Doutremepuich, Christian, et al.
Publicado: (2012)

An autopsy case of myocardial infarction due to idiopathic thrombotic thrombocytopenic purpura
por: Tasaki, Takashi, et al.
Publicado: (2015)

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera
por: Pósfai, Éva, et al.
Publicado: (2016)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Myocardial infarction due to thrombotic occlusion despite anticoagulation in Kawasaki disease – a case report
por: van Stijn, Diana, et al.
Publicado: (2022)

Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST‐segment elevation myocardial infarction
por: Bøtker, Hans Erik, et al.
Publicado: (2020)

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia
por: Bourguignon, Alex, et al.
Publicado: (2021)

Unusual Presentation of Thrombotic Thrombocytopenic Purpura With Non-ST-Elevation Myocardial Infarction
por: Gheith, Zaid, et al.
Publicado: (2022)

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes
por: Farag, Mohamed, et al.
Publicado: (2015)

Spontaneous Coronary Artery Dissection: The Phantom Menace
por: Spinthakis, Nikolaos, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fnqvej7s2297getcs4431u008v